Navigation Links
Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
Date:7/22/2010

SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced today that on July 20, 2010 it received a letter from the Nasdaq Stock Market stating that the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule [5450(a)(1)].  The notification of noncompliance has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market.

The Company has been provided 180 calendar days, or until January 18, 2011, to regain compliance with the minimum bid price requirement.  To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180-day grace period.  Nasdaq may, in its discretion, require the Company's common stock to maintain a closing bid price of at least $1.00 for a period in excess of ten consecutive trading days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

If the Company does not regain compliance by January 18, 2011, it will receive written notification from Nasdaq that its common stock is subject to delisting.  The Company may, at that time, appeal the delisting determination to a Nasdaq Hearings Panel.  Such a
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Poniard Pharmaceuticals Announces $6.3 Million Financing
3. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
4. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
5. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
6. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
7. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
8. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... Oct. 30, 2014 Today, DripDrop, the ... that it was awarded a two-year contract, effective ... company that serves the more than 100,000 members ... Association and Provista.  DripDrop also ... from member hospitals who attended the recent Novation ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... ,, LAIYANG, China , July 9 /PRNewswire-Asia-FirstCall/ -- ... present at the Global Hunter Securities,China Investment Conference, which takes place July 11-13, 2010 ... , , ... 2010 , , , ...
... July 8 Sysmex, a global leader ... technology, today announced a three-year, dual source urinalysis ... purchasing/leasing access to Sysmex automated urine particle analyzers, ... for Amerinet members will be provided through Sysmex ...
Cached Medicine Technology:Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 2Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 3Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- A new ... life-threatening meningococcal disease was approved by the U.S. Food ... to protect people between the ages of 10 and ... meningitidis serogroup B bacteria. The bacteria can ... the spinal cord and brain. It is a leading ...
(Date:10/29/2014)... cancer medications are linked with an increased risk of ... failure or prior heart attacks. Published in BJU ... weigh the benefits and risks of the drugs. ... male hormones in the body to prevent them from ... prostate cancer. Despite its anticancer effects, ADT has been ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... released important information about epilepsy and seizure,disorders to dispel ... Edward Kennedy (D-Mass)., Senator Kennedy, 76, one of ... a seizure on Saturday. A seizure is a,disturbance in ... Americans,will have a single seizure at some point in ...
... foods, such as bread, pasta, often goes unnoticed , , ... lead to improved diagnosis and treatment of celiac disease, ... meeting in San Diego. , Celiac disease, which ... an autoimmune disorder in the small intestine triggered by ...
... developing reliable genetic tests to guide lung cancer treatment ... recently evaluated the ability of five high-risk genetic profiles, ... recur in patients whose non-small cell lung cancer was ... findings at the American Thoracic Societys 2008 International Conference ...
... 19 Roche Diagnostics today announced,that Quest Diagnostics ... of,diagnostic testing, information and services, has signed a ... TaqMan(R) HIV-1 Test for,HIV viral load testing., ... effects of,antiretroviral therapy by measuring changes in HIV-1 ...
... Risks and Identifies ... Approaches to Manage Those Risks, SCHAUMBURG, Ill., May 19 ... of gas, inflation is affecting every,American. Among the largest groups affected ... current retirees who are experiencing,soaring costs in a volatile economy., ...
... 19 On May 13, 2008, the Cancer,Prevention Coalition, ... FDA. This updates scientific information detailed in a,November 17, ... It also,documents prior knowledge of the FDA and industry ... basis of the 2008 Petition is detailed in 11 ...
Cached Medicine News:Health News:The Epilepsy Foundation Sheds Light on Seizures 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Quest Diagnostics Chooses Roche's Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide 2Health News:Inflation Ranks as Today's Top Retirement Concern 2Health News:Inflation Ranks as Today's Top Retirement Concern 3Health News:Inflation Ranks as Today's Top Retirement Concern 4Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: